Replimune (REPL) Stock Gains On Regulatory Update For Lead Therapy

In the most recent trading session, shares of Replimune Group, Inc. (NASDAQ: REPL) saw a significant increase, closing 18.89% higher at $3.335. The increase came after investors responded to the FDA’s Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for Replimune’s lead immunotherapy candidate, RP1 (vusolimogene oderparepvec), in combination with nivolumab for advanced […]

Frisco Reports
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.